# What IGF-1 LR3 did in a lab-made skin model

- Article ID: research-328
- Product: SEMA / IGF-1 LR3 (sema-igf-1-lr3-708, sema-igf-1-lr3-709)
- Canonical page: https://heritagebiolabs.com/research-library/articles/328-what-igf-1-lr3-did-in-a-lab-made-skin-model
- Product collection: https://heritagebiolabs.com/research-library/products/sema-igf-1-lr3
- Product page: https://heritagebiolabs.com/product/sema-igf-1-lr3-708
- Product page: https://heritagebiolabs.com/product/sema-igf-1-lr3-709
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains joined by peptide bonds. Some act as signals, and related proteins can have similar building blocks with different sequences. Semaglutide is a peptide that activates the GLP-1 receptor. IGF-1 LR3 is an engineered version of a growth-factor protein. A 2026 tissue-engineering study used IGF-1 LR3 to investigate how cells build a supporting matrix in reconstructed skin tissue. The other compound in the catalog entry, semaglutide, was outside that experiment. [1, 2]

The research team worked with dermal fibroblasts. These cells make collagen and other materials that help give skin its structure. The team grew reconstructed dermal tissue and compared several conditions, including exposure to IGF-1 LR3 alone or with estradiol. Measurements included collagen staining and features such as tissue thickness and mechanical properties. These were laboratory outcomes from a defined tissue model. [1]

The investigators reported that the LR3-containing conditions increased collagen deposition in the reconstructed tissue. On the cited collagen and thickness comparisons, adding estradiol did not show a significant difference from IGF-1 LR3 alone. That comparison illustrates how researchers can test the contribution of a second compound in the same experimental system. The result applies to the actual second compound and the measured outcomes. [1]

A reconstructed dermis helps researchers examine how particular cells deposit collagen. It does not reproduce the many systems that would affect how a growth factor is distributed, metabolized and received across tissues in a person. The study provides direct laboratory evidence for IGF-1 LR3 in this model. It gives no result for semaglutide plus IGF-1 LR3 or for muscle function during weight change. [1, 2]

## Sources

1. David Brownell et al. IGF-1 Increases Collagen Deposition by Dermal Fibroblasts: Applications for Tissue Engineering. Cells (publication 2026-06-02). <https://pubmed.ncbi.nlm.nih.gov/42274614/>
2. U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Drugs@FDA (publication 2026-06). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 066 - Selank and SEMA IGF-1 LR3.docx; article 328; content SHA-256 aa0310b61ac601c7f1cee1f36cd4ab19b31f5f0e1dda2b9d38fa211b4d556c84.
